Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)

Market Cap	7.34B
Revenue (ttm)	1.56B
Net Income (ttm)	293.59M
Shares Out	1.25B
EPS (ttm)	0.23
PE Ratio	25.61
Forward PE	20.78
Dividend	0.12 (2.04%)
Ex-Dividend Date	May 29, 2024

Volume	11,434,592
Average Volume	20,730,511
Open	5.93
Previous Close	5.82
Day's Range	5.93 - 6.21
52-Week Range	4.52 - 7.18
Beta	0.10
RSI	60.74
Earnings Date	Apr 19, 2025

About SHE:002550

Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers its products in the form of tablets, hard capsules, lyophilized powder and lyophilized powder injections, small-volume injections, and raw materials. It provides enzymes, including pancreatic kininogenase series, asparaginase series, and compound digestive enzyme capsule II; and polysaccharides products, such as nadroparin calcium, enoxaparin sodium, dalteparin sodium, and asparaginase and heparin sodium. The company ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1971
• Employees: 1,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002550

Financial Performance

In 2023, SHE:002550's revenue was 1.81 billion, a decrease of -21.24% compared to the previous year's 2.30 billion. Earnings were 181.86 million, a decrease of -43.77%.